Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60)
Aims The current study evaluated patient demographics and clinical characteristics that associated with HbA1c reduction following addition of one oral antidiabetic drug (OAD) to DPP4i monotherapy. Methods A retrospective study was conducted using CoDiC database. Adult T2DM patients treated with sita...
Gespeichert in:
| Veröffentlicht in: | Diabetology International 2022-01, Vol.13 (1), p.132-141 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 1 |
| container_start_page | 132 |
| container_title | Diabetology International |
| container_volume | 13 |
| creator | Kawai, Koichi Eiki, Jun-ichi Kanatsuka, Azuma Motohashi, Shinobu Wakana, Akira Hayashi, Ai Iglay, Kristy Yamazaki, Katsuya Tokita, Shigeru Maegawa, Hiroshi |
| description | Aims
The current study evaluated patient demographics and clinical characteristics that associated with HbA1c reduction following addition of one oral antidiabetic drug (OAD) to DPP4i monotherapy.
Methods
A retrospective study was conducted using CoDiC database. Adult T2DM patients treated with sitagliptin monotherapy for ≥ 6 months and adding one OAD were extracted. Association between patient characteristics at the time of add-on OAD and following HbA1c reduction was assessed.
Results
Of 444 included patients, mean age was 62 years and 33% were female. All add-on OAD classes demonstrated further HbA1c reduction (
p
|
| doi_str_mv | 10.1007/s13340-021-00514-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8733084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A711675270</galeid><sourcerecordid>A711675270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-cb40a09fe46c3efb04306aceeb14bfd7b3c4e9b419bf743cd19fb938792c1133</originalsourceid><addsrcrecordid>eNp9Ustu3SAUtKpWTZTmB7qokLpJFk4B49emUpTbV5Sqd5E9wvjYJrLBBZzofmd_qOfG6e1jUZAAwZw5M_YkyWtGLxil5bvAskzQlHKWUpozkebPkmPOapqyoiqeH85ldZSchnBHcYia0bJ4mRxlOc1rLurj5MdWRQM2Ej0or3QEb0I0OhAVgtNGRWjJg4kDMdPs3T1Me6yxpB93GiajiXY2ejeSzo2jezC2J6ptTTTOEtcRhatXI-7RtEY1gNyk9UtPoiOb7TYVSDaYxkTnyeSsiwN4Ne_2La7VrCwEIPMqMaxC4m4GwsnKBoFMMI4mLoGcXW82X0lBz18lLzo1Bjh92k-S248fbq8-pzffPn25urxJdZ7TmOpGUEXrDkShM-gaKjJaKA3QMNF0bdlkWkDdCFY3XSky3bK6a-qsKmuuGX79k-T9SjsvzQStRoloVc7eTMrvpFNG_v1izSB7dy-rMstoJZDg7InAu-8LhCgnEzTaQdtuCZIXnPOyEo-93v4DvXOLt-gOUayoK5bzElEXK6pXI0hjO4d9Nc52_6uchc7g_WXJMBaIp1jA1wLtXQgeuoN6RuU-ZnKNmcSYyceYyRyL3vzp-1DyK1QIyFZAwCfbg_8t9j-0PwHTCOJS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616981527</pqid></control><display><type>article</type><title>Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60)</title><source>EZB Free E-Journals</source><source>SpringerLink (Online service)</source><source>PubMed Central</source><creator>Kawai, Koichi ; Eiki, Jun-ichi ; Kanatsuka, Azuma ; Motohashi, Shinobu ; Wakana, Akira ; Hayashi, Ai ; Iglay, Kristy ; Yamazaki, Katsuya ; Tokita, Shigeru ; Maegawa, Hiroshi</creator><creatorcontrib>Kawai, Koichi ; Eiki, Jun-ichi ; Kanatsuka, Azuma ; Motohashi, Shinobu ; Wakana, Akira ; Hayashi, Ai ; Iglay, Kristy ; Yamazaki, Katsuya ; Tokita, Shigeru ; Maegawa, Hiroshi ; Japan Diabetes Clinical Data Management Study Group (JDDM)</creatorcontrib><description>Aims
The current study evaluated patient demographics and clinical characteristics that associated with HbA1c reduction following addition of one oral antidiabetic drug (OAD) to DPP4i monotherapy.
Methods
A retrospective study was conducted using CoDiC database. Adult T2DM patients treated with sitagliptin monotherapy for ≥ 6 months and adding one OAD were extracted. Association between patient characteristics at the time of add-on OAD and following HbA1c reduction was assessed.
Results
Of 444 included patients, mean age was 62 years and 33% were female. All add-on OAD classes demonstrated further HbA1c reduction (
p
< 0.05). The majority received biguanide (BG; 61%) or sulfonylurea (SU; 25%) add-on therapy. BG and SU groups showed a significant association between higher baseline HbA1c categories and greater HbA1c reductions (BG: − 0.24 to − 1.75%,
p
< 0.0001; SU: − 0.15 to − 2.11%,
p
< 0.0001). Lower HDL-cholesterol/higher non-HDL-cholesterol (BG), male gender (SU), and lower SBP (SU) were associated with larger HbA1c reductions. The results for baseline HbA1c (BG and SU) and gender (SU) were also confirmed by multivariate analysis.
Conclusion
The majority of Japanese T2DM patients on sitagliptin monotherapy who require an add-on OAD utilized BG or SU. There were 2 determinants of glycemic response: baseline HbA1c with BG and SU and gender with SU during add-on OAD therapy.</description><identifier>ISSN: 2190-1678</identifier><identifier>EISSN: 2190-1686</identifier><identifier>DOI: 10.1007/s13340-021-00514-5</identifier><identifier>PMID: 35059249</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Analysis ; Antidiabetics ; Care and treatment ; Cholesterol ; Demography ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes therapy ; Endocrinology ; Gas industry ; Gender ; Glycosylated hemoglobin ; High density lipoprotein ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Metabolic Diseases ; Multivariate analysis ; Original ; Original Article ; Patients ; Pharmaceutical industry ; Sitagliptin ; Sulfonylurea ; Type 2 diabetes</subject><ispartof>Diabetology International, 2022-01, Vol.13 (1), p.132-141</ispartof><rights>The Japan Diabetes Society 2021. corrected publication 2021</rights><rights>The Japan Diabetes Society 2021, corrected publication 2021.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Japan Diabetes Society 2021. corrected publication 2021.</rights><rights>The Japan Diabetes Society 2021, corrected publication 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c550t-cb40a09fe46c3efb04306aceeb14bfd7b3c4e9b419bf743cd19fb938792c1133</cites><orcidid>0000-0003-0916-2199 ; 0000-0002-4611-8149 ; 0000-0002-6363-7282 ; 0000-0002-1622-6114</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733084/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733084/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35059249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawai, Koichi</creatorcontrib><creatorcontrib>Eiki, Jun-ichi</creatorcontrib><creatorcontrib>Kanatsuka, Azuma</creatorcontrib><creatorcontrib>Motohashi, Shinobu</creatorcontrib><creatorcontrib>Wakana, Akira</creatorcontrib><creatorcontrib>Hayashi, Ai</creatorcontrib><creatorcontrib>Iglay, Kristy</creatorcontrib><creatorcontrib>Yamazaki, Katsuya</creatorcontrib><creatorcontrib>Tokita, Shigeru</creatorcontrib><creatorcontrib>Maegawa, Hiroshi</creatorcontrib><creatorcontrib>Japan Diabetes Clinical Data Management Study Group (JDDM)</creatorcontrib><title>Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60)</title><title>Diabetology International</title><addtitle>Diabetol Int</addtitle><addtitle>Diabetol Int</addtitle><description>Aims
The current study evaluated patient demographics and clinical characteristics that associated with HbA1c reduction following addition of one oral antidiabetic drug (OAD) to DPP4i monotherapy.
Methods
A retrospective study was conducted using CoDiC database. Adult T2DM patients treated with sitagliptin monotherapy for ≥ 6 months and adding one OAD were extracted. Association between patient characteristics at the time of add-on OAD and following HbA1c reduction was assessed.
Results
Of 444 included patients, mean age was 62 years and 33% were female. All add-on OAD classes demonstrated further HbA1c reduction (
p
< 0.05). The majority received biguanide (BG; 61%) or sulfonylurea (SU; 25%) add-on therapy. BG and SU groups showed a significant association between higher baseline HbA1c categories and greater HbA1c reductions (BG: − 0.24 to − 1.75%,
p
< 0.0001; SU: − 0.15 to − 2.11%,
p
< 0.0001). Lower HDL-cholesterol/higher non-HDL-cholesterol (BG), male gender (SU), and lower SBP (SU) were associated with larger HbA1c reductions. The results for baseline HbA1c (BG and SU) and gender (SU) were also confirmed by multivariate analysis.
Conclusion
The majority of Japanese T2DM patients on sitagliptin monotherapy who require an add-on OAD utilized BG or SU. There were 2 determinants of glycemic response: baseline HbA1c with BG and SU and gender with SU during add-on OAD therapy.</description><subject>Analysis</subject><subject>Antidiabetics</subject><subject>Care and treatment</subject><subject>Cholesterol</subject><subject>Demography</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes therapy</subject><subject>Endocrinology</subject><subject>Gas industry</subject><subject>Gender</subject><subject>Glycosylated hemoglobin</subject><subject>High density lipoprotein</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Metabolic Diseases</subject><subject>Multivariate analysis</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Sitagliptin</subject><subject>Sulfonylurea</subject><subject>Type 2 diabetes</subject><issn>2190-1678</issn><issn>2190-1686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9Ustu3SAUtKpWTZTmB7qokLpJFk4B49emUpTbV5Sqd5E9wvjYJrLBBZzofmd_qOfG6e1jUZAAwZw5M_YkyWtGLxil5bvAskzQlHKWUpozkebPkmPOapqyoiqeH85ldZSchnBHcYia0bJ4mRxlOc1rLurj5MdWRQM2Ej0or3QEb0I0OhAVgtNGRWjJg4kDMdPs3T1Me6yxpB93GiajiXY2ejeSzo2jezC2J6ptTTTOEtcRhatXI-7RtEY1gNyk9UtPoiOb7TYVSDaYxkTnyeSsiwN4Ne_2La7VrCwEIPMqMaxC4m4GwsnKBoFMMI4mLoGcXW82X0lBz18lLzo1Bjh92k-S248fbq8-pzffPn25urxJdZ7TmOpGUEXrDkShM-gaKjJaKA3QMNF0bdlkWkDdCFY3XSky3bK6a-qsKmuuGX79k-T9SjsvzQStRoloVc7eTMrvpFNG_v1izSB7dy-rMstoJZDg7InAu-8LhCgnEzTaQdtuCZIXnPOyEo-93v4DvXOLt-gOUayoK5bzElEXK6pXI0hjO4d9Nc52_6uchc7g_WXJMBaIp1jA1wLtXQgeuoN6RuU-ZnKNmcSYyceYyRyL3vzp-1DyK1QIyFZAwCfbg_8t9j-0PwHTCOJS</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Kawai, Koichi</creator><creator>Eiki, Jun-ichi</creator><creator>Kanatsuka, Azuma</creator><creator>Motohashi, Shinobu</creator><creator>Wakana, Akira</creator><creator>Hayashi, Ai</creator><creator>Iglay, Kristy</creator><creator>Yamazaki, Katsuya</creator><creator>Tokita, Shigeru</creator><creator>Maegawa, Hiroshi</creator><general>Springer Singapore</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0916-2199</orcidid><orcidid>https://orcid.org/0000-0002-4611-8149</orcidid><orcidid>https://orcid.org/0000-0002-6363-7282</orcidid><orcidid>https://orcid.org/0000-0002-1622-6114</orcidid></search><sort><creationdate>20220101</creationdate><title>Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60)</title><author>Kawai, Koichi ; Eiki, Jun-ichi ; Kanatsuka, Azuma ; Motohashi, Shinobu ; Wakana, Akira ; Hayashi, Ai ; Iglay, Kristy ; Yamazaki, Katsuya ; Tokita, Shigeru ; Maegawa, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-cb40a09fe46c3efb04306aceeb14bfd7b3c4e9b419bf743cd19fb938792c1133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antidiabetics</topic><topic>Care and treatment</topic><topic>Cholesterol</topic><topic>Demography</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes therapy</topic><topic>Endocrinology</topic><topic>Gas industry</topic><topic>Gender</topic><topic>Glycosylated hemoglobin</topic><topic>High density lipoprotein</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Metabolic Diseases</topic><topic>Multivariate analysis</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Sitagliptin</topic><topic>Sulfonylurea</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawai, Koichi</creatorcontrib><creatorcontrib>Eiki, Jun-ichi</creatorcontrib><creatorcontrib>Kanatsuka, Azuma</creatorcontrib><creatorcontrib>Motohashi, Shinobu</creatorcontrib><creatorcontrib>Wakana, Akira</creatorcontrib><creatorcontrib>Hayashi, Ai</creatorcontrib><creatorcontrib>Iglay, Kristy</creatorcontrib><creatorcontrib>Yamazaki, Katsuya</creatorcontrib><creatorcontrib>Tokita, Shigeru</creatorcontrib><creatorcontrib>Maegawa, Hiroshi</creatorcontrib><creatorcontrib>Japan Diabetes Clinical Data Management Study Group (JDDM)</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Academic OneFile</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetology International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawai, Koichi</au><au>Eiki, Jun-ichi</au><au>Kanatsuka, Azuma</au><au>Motohashi, Shinobu</au><au>Wakana, Akira</au><au>Hayashi, Ai</au><au>Iglay, Kristy</au><au>Yamazaki, Katsuya</au><au>Tokita, Shigeru</au><au>Maegawa, Hiroshi</au><aucorp>Japan Diabetes Clinical Data Management Study Group (JDDM)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60)</atitle><jtitle>Diabetology International</jtitle><stitle>Diabetol Int</stitle><addtitle>Diabetol Int</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>13</volume><issue>1</issue><spage>132</spage><epage>141</epage><pages>132-141</pages><issn>2190-1678</issn><eissn>2190-1686</eissn><abstract>Aims
The current study evaluated patient demographics and clinical characteristics that associated with HbA1c reduction following addition of one oral antidiabetic drug (OAD) to DPP4i monotherapy.
Methods
A retrospective study was conducted using CoDiC database. Adult T2DM patients treated with sitagliptin monotherapy for ≥ 6 months and adding one OAD were extracted. Association between patient characteristics at the time of add-on OAD and following HbA1c reduction was assessed.
Results
Of 444 included patients, mean age was 62 years and 33% were female. All add-on OAD classes demonstrated further HbA1c reduction (
p
< 0.05). The majority received biguanide (BG; 61%) or sulfonylurea (SU; 25%) add-on therapy. BG and SU groups showed a significant association between higher baseline HbA1c categories and greater HbA1c reductions (BG: − 0.24 to − 1.75%,
p
< 0.0001; SU: − 0.15 to − 2.11%,
p
< 0.0001). Lower HDL-cholesterol/higher non-HDL-cholesterol (BG), male gender (SU), and lower SBP (SU) were associated with larger HbA1c reductions. The results for baseline HbA1c (BG and SU) and gender (SU) were also confirmed by multivariate analysis.
Conclusion
The majority of Japanese T2DM patients on sitagliptin monotherapy who require an add-on OAD utilized BG or SU. There were 2 determinants of glycemic response: baseline HbA1c with BG and SU and gender with SU during add-on OAD therapy.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>35059249</pmid><doi>10.1007/s13340-021-00514-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0916-2199</orcidid><orcidid>https://orcid.org/0000-0002-4611-8149</orcidid><orcidid>https://orcid.org/0000-0002-6363-7282</orcidid><orcidid>https://orcid.org/0000-0002-1622-6114</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2190-1678 |
| ispartof | Diabetology International, 2022-01, Vol.13 (1), p.132-141 |
| issn | 2190-1678 2190-1686 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8733084 |
| source | EZB Free E-Journals; SpringerLink (Online service); PubMed Central |
| subjects | Analysis Antidiabetics Care and treatment Cholesterol Demography Diabetes Diabetes mellitus (non-insulin dependent) Diabetes therapy Endocrinology Gas industry Gender Glycosylated hemoglobin High density lipoprotein Medical research Medicine Medicine & Public Health Medicine, Experimental Metabolic Diseases Multivariate analysis Original Original Article Patients Pharmaceutical industry Sitagliptin Sulfonylurea Type 2 diabetes |
| title | Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A45%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%20characteristics%20associated%20with%20improvement%20in%20glycemic%20control%20following%20addition%20of%20an%20oral%20antidiabetic%20drug%20to%20DPP-4%20inhibitor%20monotherapy%20in%20Japanese%20patients%20with%20type%202%20diabetes%20mellitus%20(JDDM%2060)&rft.jtitle=Diabetology%20International&rft.au=Kawai,%20Koichi&rft.aucorp=Japan%20Diabetes%20Clinical%20Data%20Management%20Study%20Group%20(JDDM)&rft.date=2022-01-01&rft.volume=13&rft.issue=1&rft.spage=132&rft.epage=141&rft.pages=132-141&rft.issn=2190-1678&rft.eissn=2190-1686&rft_id=info:doi/10.1007/s13340-021-00514-5&rft_dat=%3Cgale_pubme%3EA711675270%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616981527&rft_id=info:pmid/35059249&rft_galeid=A711675270&rfr_iscdi=true |